Fast R
J Bacteriol. 1978 Dec;136(3):839-43. doi: 10.1128/jb.136.3.839-843.1978.
The incorporation of uracil into the pyrimidine ribonucleotide pools of Escherichia coli is strongly restricted under stringent conditions. Previously, we have suggested that this inhibition can be explained by the allosteric properties of uracil phosphoribosyltransferase. It has been proposed that this enzyme performs the uptake of uracil into the cell by transporting it across the cytoplasmic membrane, with the stimultaenous formation of UMP. To test this hypothesis it would be helpful to have mutants with changed regulation of uracil uptake, and in the present work, a method is introduced for the selection of such mutants. This method is based on phenotypic suppression of amber mutations by 5-fluorouracil (5FU). Mutants were isolated in an arginine-requiring strain of E. coli carrying an amber mutation in argI, the ornithine transcarbamylase gene. To facilitate the phenotypic rescue of this defective gene, mutants which overproduced ornithine transcarbamylase mRNA were isolated as a first step. The absence of exogenously added arginine causes stringent conditions, and phenotypic rescue by 5FU is, thus, prevented, unless the 5FU uptake mechanism is mutationally changed in such a manner that the drug is taken up into the cell. Three mutants in which the growth could be supported by 5FU in the absence of arginine were isolated. Two of them had acquired an increased ability to take up uracil under stringent conditions.
在严格条件下,尿嘧啶掺入大肠杆菌嘧啶核糖核苷酸库的过程受到强烈限制。此前,我们曾提出这种抑制作用可以通过尿嘧啶磷酸核糖转移酶的别构性质来解释。有人提出,该酶通过将尿嘧啶转运穿过细胞质膜,同时形成UMP,从而实现尿嘧啶进入细胞。为了验证这一假设,获得尿嘧啶摄取调节改变的突变体将很有帮助,在本研究中,引入了一种选择此类突变体的方法。该方法基于5-氟尿嘧啶(5FU)对琥珀突变的表型抑制。在携带精氨酸I(鸟氨酸转氨甲酰酶基因)琥珀突变的大肠杆菌精氨酸需求菌株中分离出突变体。为了促进这个缺陷基因的表型拯救,第一步先分离出过量产生鸟氨酸转氨甲酰酶mRNA的突变体。除非5FU摄取机制发生突变,使药物能够被细胞摄取,否则外源性添加精氨酸的缺失会导致严格条件,从而阻止5FU的表型拯救。分离出了三个在无精氨酸时能由5FU支持生长的突变体。其中两个在严格条件下摄取尿嘧啶的能力有所增强。